Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has Quantum Genomics Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALQGC is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ALQGC's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ALQGC underperformed the French Biotechs industry which returned 21.1% over the past year.
Return vs Market: ALQGC underperformed the French Market which returned 36.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Quantum Genomics Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Quantum Genomics Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALQGC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALQGC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALQGC is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ALQGC is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALQGC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALQGC is good value based on its PB Ratio (3.5x) compared to the FR Biotechs industry average (4.1x).
How is Quantum Genomics Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALQGC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: ALQGC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALQGC's is expected to become profitable in the next 3 years.
Revenue vs Market: ALQGC's revenue (34.7% per year) is forecast to grow faster than the French market (7% per year).
High Growth Revenue: ALQGC's revenue (34.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALQGC is forecast to be unprofitable in 3 years.
How has Quantum Genomics Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALQGC is currently unprofitable.
Growing Profit Margin: ALQGC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALQGC is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare ALQGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALQGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: ALQGC has a negative Return on Equity (-42.52%), as it is currently unprofitable.
How is Quantum Genomics Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALQGC's short term assets (€33.5M) exceed its short term liabilities (€7.1M).
Long Term Liabilities: ALQGC's short term assets (€33.5M) exceed its long term liabilities (€731.8K).
Debt to Equity History and Analysis
Debt Level: ALQGC's debt to equity ratio (0.01%) is considered satisfactory.
Reducing Debt: ALQGC's debt to equity ratio has reduced from 0.01% to 0.01% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALQGC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALQGC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23% each year
What is Quantum Genomics Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALQGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALQGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALQGC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALQGC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALQGC's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Philippe Milon (60 yo)
Dr. Jean-Philippe Milon, PhD., has been the Chief Executive Officer at Quantum Genomics Société Anonyme since April 06, 2018, and serves as its MD, and has also been its Director since June 17, 2019. Dr. M...
Experienced Management: ALQGC's management team is considered experienced (3.2 years average tenure).
Experienced Board: ALQGC's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.7%.
Quantum Genomics Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Quantum Genomics Société Anonyme
- Ticker: ALQGC
- Exchange: ENXTPA
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €95.254m
- Shares outstanding: 26.89m
- Website: https://www.quantum-genomics.com
Number of Employees
- Quantum Genomics Société Anonyme
- 33, rue Marbeuf
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to tr...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 18:42|
|End of Day Share Price||2021/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.